2022 American Transplant Congress
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
*Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…2022 American Transplant Congress
Kidney Allograft Injury is Reflected in the DNA Cargo of Urinary Extracellular Vesicles
*Purpose: Following cell injury, donor-derived cell-free DNA (ddcfDNA) is increased in the urine of kidney transplant recipients. DNA containing urinary extracellular vesicles (uEVs) are relevant…2022 American Transplant Congress
Leveraging Single-Cell Signatures in Kidney Transplant Biopsies Uncovers Immunological Heterogeneity Within Rejection Phenotypes
*Purpose: Rejection of the kidney allograft is hallmarked by the accumulation of inflammatory cells within the renal architecture, leading to microvascular or tubulointerstitial inflammation. However,…2022 American Transplant Congress
Parainfluenza Type 3 Infection in Solid Organ Transplant Recipients
*Purpose: Respiratory viral infection, including COVID-19, causes significant morbidity and mortality in solid organ transplant recipients (SOTR), however, the data of parainfluenza virus (PIV) type…2022 American Transplant Congress
Donor-Derived IL-33 Plays a Critical Role in Lung Allograft Acceptance
*Purpose: IL-33 is considered an alarmin secreted in response to tissue damage. While it is elaborated by the lung allograft as part of ischemia-reperfusion injury…2022 American Transplant Congress
The Correlation of Dd-cfdna and Donor Specific Antibodies in Kidney Transplant Recipients
Johns Hopkins Hospital, Baltimore, MD
*Purpose: Donor derived cell free DNA (dd-cfDNA) is increasingly being utilized to discern the presence of rejection in kidney transplant recipients (KTRs). There continues to…2022 American Transplant Congress
Safety of Stimulant Use in Heart Transplant Recipients
*Purpose: FDA-approved prescribed stimulants are purported to increase risk of cardiovascular (CV) adverse events, particularly arrhythmias and sudden cardiac death. Debate exists regarding the safety…2022 American Transplant Congress
The Relative Association of Clinical Variables and Histologic Lesions with Molecular Rejection in Kidney Transplant Biopsies
*Purpose: Availability of molecular assessment (MMDx) independent of conventional variables (time, clinical, histologic, and HLA antibody) presents an opportunity to re-assess the relative strength of…2022 American Transplant Congress
Surveillance of Donor-Derived Cell-Free DNA Throughout Treatment of Acute Rejection in Pediatric Renal Transplant Recipients
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a dynamic plasma biomarker for allograft rejection with limited data in pediatric renal transplant recipients and few reports describing…2022 American Transplant Congress
The Natural History of De Novo DSA After Kidney Transplantation
*Purpose: De novo donor-specific antibodies(dnDSA) are key in the diagnosis of antibody-mediated rejection(ABMR) and are related to graft loss(GL). Luminex® provides semi-quantitative information with the…
American Transplant Congress abstracts